UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
Schedule
14F-1
INFORMATION
STATEMENT
PURSUANT
TO SECTION 14(f) OF THE
SECURITIES
EXCHANGE ACT OF 1934
AND
RULE 14f-1 THEREUNDER
THE
GREATER CANNABIS COMPANY, INC.
(Exact
name of registrant as specified in its corporate charter)
Commission
File No.: 333-218854
| Florida |
|
30-0842570 |
(State
or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
2833
Smith Ave. Ste 333
Baltimore,
MD 21209
(Address
of principal executive offices)
(443)
738-4051
(Registrant’s
telephone number, including area code)
Approximate
Date of Mailing: July 6, 2026
THE
GREATER CANNABIS COMPANY, INC.
2833
Smith Avenue Suite 333
Baltimore,
MD 21209
INFORMATION
STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER
Schedule
14f-1
You
are urged to read this Information Statement carefully and in its entirety. However, you are not required to take any action in connection
with this Information Statement. References throughout this Information Statement to “Company,” “THE GREATER
CANNABIS COMPANY, INC.” “we,” “us,” and “our” include THE GREATER CANNABIS COMPANY,
INC.
INTRODUCTION
This
information statement (this “Information Statement”) is being furnished pursuant to Section 14(f) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 14f-1 promulgated thereunder, in connection with proposed
changes in a majority of the membership of our board of directors (the “Board”) as a result of the Share Purchase
transaction described below. The date of this Information Statement is June 29, 2026.
On
the Closing Date of the Share Purchase transaction, Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the
Board, and a member of the Board of Directors of the Company. Aitan Zacharin resigned from all officer positions effective immediately
upon such appointment and agreed to remain as a member of the Board of Directors solely until the expiration of the ten (10) day period
required under Rule 14f-1. Upon expiration of such period, Mr. Zacharin’s resignation as a director will become effective and Mr.
Sanchez Talavera will remain as a director of the Company and continue to serve as Chairman of the Board and Chief Executive Officer
until such time as additional directors may be appointed.
As
of June 29, 2026, Trafalgar Asset Management, LLC, Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera
(the “Controlling Shareholder”) purchased a controlling interest in the Company and may unilaterally determine the election
of the Board and other substantive matters requiring approval of the Company’s stockholders. The Controlling Shareholder purchased
(i) 7,628,665 shares of Series A Preferred Stock; and (ii) 1,000 shares of Series B Preferred Stock from certain shareholders of the
Company (the “Share Purchase”). Contemporaneously with the Share Purchase, certain indebtedness of the Company was compromised,
settled, canceled, and extinguished pursuant to Debt Cancellation and Release Agreements entered into by the Company and the applicable
creditors.
Pursuant
to the terms of the Share Purchase: (a) the Controlling Shareholder acquired a controlling interest in the issued and outstanding capital
stock of the Company; and (b) the Share Purchase qualifies as a transaction in securities exempt from registration or qualification under
the Securities Act of 1933, as amended (the “Securities Act”), and under the applicable securities laws of the state
or jurisdiction where the Controlling Shareholder resides.
At
the closing of the Share Purchase, there was a change in our Board and executive officers. Effective upon the Closing Date, Porfirio
Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company.
Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the
Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1. Upon expiration of such period,
Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the
Company.
No
action is required by our stockholders in connection with this Information Statement. However, Section 14(f) of the Exchange Act and
Rule 14f-1 promulgated thereunder, requires the mailing to our stockholders of the information set forth in this Information Statement
at least ten (10) days prior to the date a change in a majority of our directors occurs (otherwise than at a meeting of our stockholders).
WE
ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
VOTING
SECURITIES
Our
authorized capital stock consists of: (i) 2,000,000,000 shares of Common Stock, par value $0.001 per share, of which 994,379 shares are
issued and outstanding as of June 29, 2026; (ii) 10,000,000 shares of Series A Preferred Stock, of which 7,628,665 shares are issued
and outstanding as of June 29, 2026; and (iii) 1,000 shares of Series B Preferred Stock, of which 1,000 shares are issued and outstanding
as of June 29, 2026. Each share of Common Stock is entitled to one vote per share. Each share of Series A Preferred Stock is entitled
to 1.76 votes per share. The outstanding shares of Series B Preferred Stock collectively are entitled to fifty-one percent (51%) of all
votes entitled to be cast by the Company’s shareholders.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth certain information regarding the beneficial ownership of our voting securities as of June 29, 2026 by (i)
each person (or group of affiliated persons) who is known by us to beneficially own more than five percent of the aggregate voting power
of our outstanding voting securities, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive
officers and director nominees as a group. Beneficial ownership is determined in accordance with SEC rules and generally includes voting
or investment power with respect to securities. Unless otherwise noted, the principal address of each of the stockholders, directors
and officers listed below is The Greater Cannabis Company, Inc., 2833 Smith Ave. Ste 333, Baltimore, MD 21209.
Name | |
Sole Voting and Investment Power | | |
Percent of Class Outstanding | | |
Percentage of Aggregate Voting Power | |
| Trafalgar Asset Management, LLC(1) | |
| | | |
| | | |
| | |
| Common Stock | |
| 0 | | |
| 0.00 | % | |
| 0.00 | % |
| Series A Preferred Stock | |
| 7,628,665 | | |
| 100 | % | |
| 45.62 | % |
| Series B Preferred Stock | |
| 1,000 | | |
| 100 | % | |
| 51.00 | % |
| Directors and executive officers as a group (1 person) | |
| | | |
| | | |
| | |
| Common Stock | |
| 0 | | |
| 0.00 | % | |
| 0.00 | % |
| Series A Preferred Stock | |
| 7,628,665 | | |
| 100 | % | |
| 45.62 | % |
| Series B Preferred Stock | |
| 1,000 | | |
| 100 | % | |
| 51.00 | % |
| Total Aggregate Voting Power | |
| | | |
| | | |
| 96.62 | % |
(1)
Trafalgar Asset Management, LLC is controlled by Porfirio Sanchez Talavera, who serves as Chairman of the Board and Chief Executive
Officer of the Company. Trafalgar Asset Management, LLC does not beneficially own any shares of the Company’s Common Stock.
Through its ownership of all outstanding shares of the Company’s Series A Preferred Stock and Series B Preferred Stock,
Trafalgar Asset Management, LLC possesses approximately 96.62% of the aggregate voting power of the Company’s outstanding
voting securities as of June 29, 2026, based upon 994,379 shares of Common Stock outstanding, each share of Series A Preferred Stock
being entitled to 1.76 votes per share, and the outstanding shares of Series B Preferred Stock collectively being entitled to 51% of
all votes entitled to be cast.
CHANGES
TO THE BOARD OF DIRECTORS
At
the closing of the Share Purchase, there was a change in our Board and executive officers. Effective upon the Closing Date, Porfirio
Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company.
Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the
Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1. Upon expiration of such period,
Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the
Company.
Porfirio
Sanchez Talavera was appointed to the Board of Directors of the Company in connection with the Share Purchase and was not a member of
the Board of Directors prior thereto. Prior to the Share Purchase, Mr. Sanchez Talavera did not hold any position with the Company and
had not been involved in any transaction with the Company or any of its directors, executive officers, affiliates, or associates that
is required to be disclosed pursuant to the rules and regulations of the Securities and Exchange Commission. To the best of the Company’s
knowledge, Mr. Sanchez Talavera has not, during the past five years, (i) been convicted in a criminal proceeding (excluding traffic violations
and similar misdemeanors), or (ii) been a party to any judicial or administrative proceeding that resulted in a judgment, decree, or
final order enjoining him from future violations of, or prohibiting activities subject to, federal or state securities laws, or finding
any violation of federal or state securities laws.
The
Board currently consists of two directors: Aitan Zacharin and Porfirio Sanchez Talavera. Upon expiration of the ten (10) day period prescribed
by Rule 14f-1, Mr. Zacharin’s resignation will become effective and Mr. Sanchez Talavera will remain as the sole director. There
are no family relationships among directors and executive officers. Also provided herein are brief descriptions of the business experience
of each director and executive officer during the past five years and an indication of directorships held by each director in other companies
subject to the reporting requirements under the federal securities laws.
Directors
prior to the Share Purchase
| Name |
|
Age |
|
Position |
| Aitan
Zacharin |
|
42 |
|
President,
Chief Executive Officer, Treasurer and Director |
Aitan
Zacharin, Former President, Chief Executive Officer, Treasurer and Director. Mr. Zacharin is an experienced executive with broad
knowledge in building and managing technology, biopharmaceutical, healthcare and consumer products businesses. Mr. Zacharin has founded
a number of companies, and has seen them through successful listings in the public markets, with collective valuations of over $1 billion.
Mr. Zacharin has been advising and investing in early to mid-stage startups, and assisting them with development, capitalization, accelerating
growth, and turnaround strategies. He specializes in strategic acquisitions, structuring complex transactions, reverse mergers, and brings
domestic and international experience in operations, accounting, audit preparation, due diligence, capital raising and restructuring,
debt financing, and mergers and acquisitions. In 2012 he co-founded Fuse Science, an innovative biotechnology company and was responsible
for growth of the business from its conceptual stage to a publicly traded CPG and biotech business with multiple subsidiaries. He structured
pivotal deals with key partners, which led to the company successfully raising over $20 million to commercialize its products, including
brand ambassador agreements with 26 sports celebrities, including world renowned athlete Tiger Woods. He successfully exited from the
company, which had reached a $110 million valuation. In 2014, Mr. Zacharin was appointed to the Board of Directors for Mediconecta, the
largest telehealth Company in Latin America serving millions of patients with on-demand, high quality healthcare. Within six months,
Mr. Zacharin facilitated and negotiated an eight figure buyout offer from Teladoc (NASDAQ: TDOC), the world’s largest telehealth
company, just prior to its IPO. In 2015, Mr. Zacharin became the managing partner of Secure Hosting LLC, a blockchain mining company
with a co-location mining farm in North Carolina. After two years of scaling out the operations to nearly $15,000,000 in assets, he successfully
structured the sale of the company to a leading publicly traded blockchain mining company. In 2017, Mr. Zacharin founded GCANRx (OTC:
GCAN), a publicly traded biopharmaceutical company focused on repurposing a highly bioavailable transmucosal drug delivery system that
had previously been commercialized in partnership with Novartis. Mr. Zacharin repurposed the platform technology for use in cannabinoid
therapeutics. He then negotiated a worldwide exclusive license from Shaare Zedek Scientific, the licensing arm of one of Israel’s
largest research hospitals, for a cannabinoid-based therapeutic used in treating neuropsychiatric disorders. The therapeutic was invented
by world-renowned cannabis researcher, Dr. Adi Aran, M.D. The Company is currently in the final stages of regulatory approval for a 100
patient Phase 2 clinical study for the treatment of autism related spectrum disorders. In 2018, Mr. Zacharin became a shareholder in
sports technology company, Slinger (NASDAQ: CNXA). The company manufactures an innovative, patented sports product called the Slinger
Bag, which raised $1 million through a highly successful Kickstarter campaign. Mr. Zacharin was tasked by the founder to take the company
public. The Company was led by the past- CEO of global tennis company Prince. Within the first 18 months of operations the company grew
to a global footprint of 65 countries, signed $250 million in distribution agreements, and achieved a market cap of over $400 million.
Throughout the growth of the company, Mr. Zacharin served as the head of investor relations and was instrumental in raising the company
over $27 million from leading Wall Street investors, and overseeing the IR strategy, which led to the stock rising over 1,700% from its
listing price. Mr. Zacharin was actively involved in Slinger’s acquisition of three companies, most notably a Softbank and Verizon
Ventures backed artificial intelligence sports company for $100 million. Mr. Zacharin led the effort of putting together a team, which
successfully uplisted the Company from the OTC Markets to the Nasdaq. In 2019, Mr. Zacharin joined an investor group who acquired Solstice
Sunglasses, the second largest sunglasses retailer in the US, to list the company’s shares on the public markets. Mr. Zacharin
led the merger of Solstice with a public vehicle, which enabled a multi-million dollar round of financing for the retailer. In 2020,
Mr. Zacharin identified, structured and facilitated the acquisition of a luxury, multi-state substance abuse facility. Mr. Zacharin secured
financing for the $18 million acquisition with a combination of investments from high net worth individuals and a loan facility from
a speciality banking lender. The company subsequently purchased two additional drug rehab portfolios, and grew to become a leading multi-state
operator in the drug rehabilitation industry. In 2021, Mr. Zacharin became the co-founder and CEO of PlasmaCure, a groundbreaking medical
device company focused on R&D and commercialization of an oncology treatment licensed from GW University. Mr. Zacharin holds dual
degrees from the University of South Florida. He serves in an executive capacity to two publicly listed companies, and maintains various
board non-profit board appointments.
Director
Appointee
| Name |
|
Age |
|
Position |
| |
|
|
|
|
| Porfirio
Sanchez Talavera |
|
39 |
|
Chairman
of the Board and Chief Executive Officer |
Mr.
Porfirio Sánchez Talavera, Chairman of the Board and Chief Executive Officer. Mr. Sánchez-Talavera is a Managing Partner
of Trafalgar Asset Management, a private merchant investment firm established in 1996 that builds, acquires, and operates companies across
regulated financial services, telecommunications infrastructure, restructuring, and special situations. Under his leadership, the firm
has completed transactions in excess of US$2.5 billion in aggregate transaction value. Within the TAM platform, Mr. Sánchez-Talavera
is the founder and controlling shareholder of Grupo Trafalgar, the firm’s financial services holding company in Mexico, comprising
regulated financial institutions engaged in electronic payments, deposit-taking, lending, and brokerage activities. Since January 2019,
he has served as Chairman of the Board of Grupo Trafalgar, overseeing corporate strategy, capital allocation, regulatory affairs, and
the expansion of the group’s licensed financial infrastructure. As part of that strategy, from 2021 to 2023 the firm founded and
developed Trafalgar Digital, an electronic payment fund institution (Institución de Fondos de Pago Electrónico, or “IFPE”)
authorized under Mexico’s Fintech Law. Trafalgar’s sale of Trafalgar Digital to Walmart de México y Centroamérica
was completed in April 2023 and represented one of the notable transactions in Mexico’s regulated fintech sector. The firm’s
telecommunications vertical reflects a longstanding thesis in asset-light infrastructure serving underserved, high-cost markets. From
June 2014 through December 2018, Mr. Sánchez-Talavera served as Chief Executive Officer of Cape Point Holdings, a telecommunications
investment and infrastructure company headquartered in Los Angeles, California, focused on satellite communications and broadband infrastructure
projects in underserved markets. During his tenure, Cape Point Holdings managed in excess of US$25 million in capital and developed a
telecommunications rights portfolio with an estimated value exceeding US$1 billion.
CORPORATE
GOVERNANCE
Committees
of the Board Of Directors
We
are currently quoted on the OTCID tier of OTC Markets Group Inc. under the symbol “GCAN”. The OTCID does not have any requirements
for establishing any committees. For this reason, we have not established any committees. All functions of an audit committee, nominating
committee and compensation committee are and have been performed by our board of directors.
Our
Board believes that, considering our size, decisions relating to director nominations can be made on a case-by-case basis by all members
of the Board without the formality of a nominating committee or a nominating committee charter. To date, we have not engaged third parties
to identify or evaluate or assist in identifying potential nominees, although we reserve the right to do so in the future.
The
Board does not have an express policy with regard to the consideration of any director candidates recommended by shareholders since the
Board believes that it can adequately evaluate any such nominees on a case-by-case basis; however, the Board will evaluate shareholder-recommended
candidates under the same criteria as internally generated candidates. Although the Board does not currently have any formal minimum
criteria for nominees, substantial relevant business and industry experience would generally be considered important, as would the ability
to attend and prepare for board, committee and shareholder meetings. Any candidate must state in advance his or her willingness and interest
in serving on the board of directors.
Following
the Effective Date, we intend to appoint such persons and form such committees as are required to meet the corporate governance requirements
imposed by the national securities exchanges. Therefore, we intend that a majority of our directors will eventually be independent directors.
Additionally, we will adopt charters relative to each such committee. Following the Share Purchase, until further determination by our
board of directors, the full board of directors will undertake the duties of the audit committee, compensation committee and nominating
committee.
Director
Independence
Presently,
we are not required to comply with the director independence requirements of any securities exchange. In determining whether our directors
are independent, however, we intend to comply with the rules of the NYSE AMEX (formerly known as the American Stock Exchange). The board
of directors also will consult with counsel to ensure that the board of directors’ determinations is consistent with those rules
and all relevant securities and other laws and regulations regarding the independence of directors, including those adopted under the
Sarbanes-Oxley Act of 2002 with respect to the independence of future audit committee members. The NYSE AMEX listing standards define
an “independent director” generally as a person, other than an officer of a company, who does not have a relationship with
the company that would interfere with the director’s exercise of independent judgment.
We
do not currently satisfy the “independent director” requirements of the NYSE AMEX, which requires that a majority of a company’s
directors be independent. However, our board of directors is in the process of searching for suitable candidates to appoint as additional
members, each of whom will satisfy such independence requirements.
EXECUTIVE
OFFICERS
In
connection with the Share Purchase, Mr. Aitan Zacharin resigned from all officer positions effective immediately upon the appointment
of Mr. Porfirio Sanchez Talavera as Chief Executive Officer of the Company and agreed to remain as a member of the Board of Directors
solely until the expiration of the ten (10) day period required under Rule 14f-1, at which time his resignation as a director shall become
effective.
A
brief description of the previous business experience of Mr. Porfirio Sanchez Talavera is provided above in the Changes to our Board
of Directors section of this Information Statement. A brief description of the business experience of our other executive officers
is included below.
SECTION
16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section
16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, and persons who beneficially
own more than 10% of a registered class of our equity securities, to file reports of beneficial ownership and changes in beneficial ownership
of our securities with the SEC on Forms 3 (Initial Statement of Beneficial Ownership), 4 (Statement of Changes of Beneficial Ownership
of Securities) and 5 (Annual Statement of Beneficial Ownership of Securities). Directors, executive officers and beneficial owners of
more than 10% of our common stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms that they file.
Except as otherwise set forth herein, based solely on review of the copies of such forms furnished to us, or written representations
that no reports were required, we believe that for the fiscal year ended December 31, 2025, all of our executive officers, directors
and greater-than-ten percent stockholders complied with Section 16(a) filing requirements applicable to them.
COMPENSATION
OF DIRECTORS AND EXECUTIVE OFFICERS
EXECUTIVE
COMPENSATION
Summary
Compensation Table
The
following table sets forth compensation information concerning all cash and non-cash compensation awarded to, earned or paid to certain
of all executive officers and other key employees of the Company who were serving as of the date of this Information Statement for services
in all capacities during the last two (2) completed fiscal years ended December 31, 2025 and 2024. The compensation listed below was
paid to our officers by the Company. The following information is calculated in U.S. dollars, bonus awards, the number of stock options
granted and certain other compensation, if any, whether paid or deferred.
THE
GREATER CANNABIS COMPANY, INC. COMPENSATION SUMMARY
| Name and Principal Position | |
Fiscal Year | | |
Salary ($) | | |
Bonus | | |
Option Awards | | |
All Other Compensation | | |
Total ($) | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| Aitan Zacharin, Former | |
2026 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
| President, Chief Executive | |
2025 | | |
$ | 120,000 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
| Officer, Treasurer and Director | |
2024 | | |
$ | 120,000 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
| | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Porfirio Sanchez Talavera | |
2026 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
| Current Chief Executive Officer | |
2025 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
| and Chairman of the Board | |
2024 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | |
Outstanding
Equity Awards at Fiscal Year End
There
are no outstanding equity awards at June 29, 2026.
Option
Plan
There
are no stock options and no common shares set aside for any stock option plan.
Director
Compensation
The
Greater Cannabis Company, Inc. has not yet provided any compensation to its directors in the fiscal year ended December 31, 2026. The
Company may establish certain compensation plans (e.g. options, cash for attending meetings, etc.) with respect to directors in the future.
Other than disclosed herein, prior to the Share Purchase, Aitan Zacharin, the sole director and officer of the Company did not receive
compensation for his services.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Common
Stock Transaction
As
of June 29, 2026, Trafalgar Asset Management, LLC, Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera
(the “Controlling Shareholder”) purchased a controlling interest in the Company and may unilaterally determine the election
of the Board and other substantive matters requiring approval of the Company’s stockholders. The Controlling Shareholder purchased
(i) 7,628,665 shares of Series A Preferred Stock; and (ii) 1,000 shares of Series B Preferred Stock from certain shareholders of the
Company (the “Share Purchase”). Contemporaneously with the Share Purchase, certain indebtedness of the Company was compromised,
settled, canceled, and extinguished pursuant to Debt Cancellation and Release Agreements entered into by the Company and the applicable
creditors.
Review,
Approval and Ratification of Related Party Transactions
We
had not adopted, prior to the Share Purchase, formal policies and procedures for the review, approval or ratification of related party
transactions, such as those described above, with our executive officers, directors and significant shareholders. However, we intend
that such transactions will, on a going-forward basis, be subject to the review, approval or ratification of the independent directors
serving on our board of directors, or an appropriate committee thereof.
INDEMNIFICATION
OF DIRECTORS AND OFFICERS
Florida
law and the Company’s Bylaws provide that the Company will indemnify, to the fullest extent permitted by applicable law, any person,
and the estate and personal representative of any such person, against all liability and expense (including attorneys’ fees and
costs of litigation) incurred by reason of the fact that such person is or was a director or officer of the Company or, while serving
as a director or officer of the Company, is or was serving at the request of the Company as a director, officer, partner, trustee, employee,
fiduciary, or agent of, or in any similar managerial or fiduciary position of, another domestic or foreign corporation or other entity
or of an employee benefit plan.
NO
STOCKHOLDER ACTION REQUIRED
This
Information Statement is being provided for informational purposes only, and does not relate to any meeting of stockholders. Neither
applicable securities laws, nor the corporate laws of the State of Florida require approval of the transactions contemplated by the Share
Purchase. No vote or other action is being requested of the Company’s stockholders. This Information Statement is provided for
informational purposes only.
STOCKHOLDER
COMMUNICATIONS WITH DIRECTORS
Stockholders
who want to communicate with our Board or any individual director can write to:
THE
GREATER CANNABIS COMPANY, INC.
2833
Smith Ave. Ste 333
Baltimore,
MD 21209
Your
letter should indicate that you are a stockholder of the Company. Depending on the subject matter, management will:
| |
● |
Forward
the communication to the Director to whom it is addressed; |
| |
|
|
| |
● |
Attempt
to handle the inquiry directly; or |
| |
|
|
| |
● |
Not
forward the communication if it is primarily commercial in nature or if it relates to an improper or irrelevant topic. |
At
each Board meeting, a member of management presents a summary of all communications received since the last meeting that were not forwarded
and makes those communications available to the Directors on request.
WHERE
YOU CAN FIND MORE INFORMATION
We
file reports with the SEC. These reports, including annual reports, quarterly reports as well as other information we are required to
file pursuant to securities laws. You may read and copy materials we file with the SEC at the SEC’s Public Reference Room at 100
F. Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC
at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC at http://www.sec.gov.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this information statement on Schedule 14F-1
to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:
July 6, 2026
| |
THE
GREATER CANNABIS COMPANY, INC. |
| |
|
|
| |
By: |
/s/
Porfirio Sanchez Talavera |
| |
Name: |
Porfirio
Sanchez Talavera |
| |
Title: |
Chief
Executive Officer |
